ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference

By September 28, 2017News, Uncategorized

ProMIS Neurosciences, Inc.

NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE
ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference

Presentation highlights the use ProMIS’ proprietary discovery platform to identify novel therapeutic targets on misfolded proteins in multiple neurodegenerative diseases

TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 28, 2017– ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced that Neil Cashman, MD, Professor and Canada Research Chair, University of British Columbia and Chief Scientific Officer, ProMIS Neurosciences, will present today at the 3rd Annual Neuroscience R&D Technologies Conference: Exploring Cutting-edge Technologies in Pre-clinical Neuroscience  Studies.

Dr. Cashman’s presentation, entitled Misfolding Proteins in Neurodegenerative Diseases describes the roles of toxic misfolded proteins as underlying drivers of multiple neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).

Commenting on the presentation, Eugene Williams, ProMIS Executive Chairman, stated, “We are delighted with the international recognition Neil Cashman is receiving for his important work in neurodegenerative diseases. Using ProMIS’ proprietary discovery platform across a range of neurodegenerative diseases, Dr. Cashman and our team have identified novel therapeutic targets on toxic misfolded proteins, including Amyloid beta oligomers in Alzheimer’s disease, TDP43 in ALS, and alpha synuclein in Parkinson’s disease. Antibodies selectively binding these novel targets, such as ProMIS’ validated lead product candidate for Alzheimer’s disease, PMN310, offer an exciting approach to the development of potential best-in-class therapeutics.”

The 3rd Annual Neuroscience R&D Technologies Conference, to be held in London, UK, September 28-29, 2017, is focused on sharing current market trends, technological advancements, and future challenges in pre-clinical neuroscience research. The conference gathers leading experts from the pharmaceutical industry and research institutes to evaluate the latest technologies in neuroscience R&D with expert keynote presentations, live case studies, and breakthrough panel discussions. 

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a TSX listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company’s website at:

www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

 

For media inquiries, please contact:

 

Scott Santiamo
RussoPartners/LLC
Scott.Santiamo@russopartnersllc.com
Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

David.Schull@russopartnersllc.com

Tel. 858 717-2310

 

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

nick@alpineequityadv.com

Tel. 617 901-0785

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Elliot.goldstein@promisneurosciences.com

Tel. 415 341-5783